SCHEMBL6726586

SCHEMBL6726586

Cc1cc(Cl)ccc1NC(=O)C(NC(=O)O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 2/20 0.51
ALPL P05186 1/20 0.51
ALOX12 P18054 1/20 0.51
RECQL P46063 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
ALDH1A1 P00352 5/20 0.47
NPSR1 Q6W5P4 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 1/20 0.47
CDC7 O00311 1/20 0.46
EEF2K O00418 1/20 0.46
PLK4 O00444 1/20 0.46
AURKA O14965 1/20 0.46
PDPK1 O15530 1/20 0.46
DAPK3 O43293 1/20 0.46
DYRK3 O43781 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718465 0.86 MEN1 (0.55) MAPTHTTLMNAALOX12ALDH1A1
SCHEMBL8338388 0.86 CTSS (0.54) MAPTHTTLMNAALPLALOX12
SCHEMBL6727015 0.83 CYP1A2 (0.53) MAPTHTTLMNAALDH1A1NPSR1
SCHEMBL6717049 0.82 MAPT (0.52) MAPTHTTLMNAALPLALOX12
SCHEMBL6719076 0.81 MAPT (0.56) MAPTHTTLMNAALPLALOX12
SCHEMBL6717041 0.81 ALOX12 (0.52) MAPTHTTLMNAALPLALOX12
SCHEMBL6718664 0.80 ALDH1A1 (0.50) MAPTHTTLMNAALPLALOX12
SCHEMBL6824814 0.79 KCNQ2 (0.58) MAPTLMNATAS1R3TAS1R1ALDH1A1
SCHEMBL6715725 0.79 MEN1 (0.54) HTTALDH1A1SMN1; SMN2
SCHEMBL6824801 0.78 BRD4 (0.60) MAPTHTTLMNARECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MAPT 694/4885HTT 284/4885LMNA 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.